Contact
searchSearch
HMP Global

Thyroid Cancer

Robert Flavell, MD, PhD, UCSF
Videos
2025 ATA Guideline Updates for Differentiated Thyroid Cancer: What Oncologists Need to Know
02/12/2026
Robert Flavell, MD, PhD
Robert Flavell, MD, PhD, reviews the 2025 ATA guidelines for differentiated thyroid cancer, highlighting updated risk stratification, refined recommendations for radioactive iodine use, expanded use of SPECT/CT imaging, and new guidance on...
Robert Flavell, MD, PhD, reviews the 2025 ATA guidelines for differentiated thyroid cancer, highlighting updated risk stratification, refined recommendations for radioactive iodine use, expanded use of SPECT/CT imaging, and new guidance on...
Robert Flavell, MD, PhD, reviews...
02/12/2026
Radiopharmaceutical Education Institute
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Radiopharmaceutical Education Institute
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Radiopharmaceutical Education Institute
Luz Castellanos, MD
Videos
Omitting Adjuvant Radioactive Iodine for Select Patients With Pediatric Papillary Thyroid Carcinoma
02/27/2025
Luz Castellanos, MD
Luz Castellanos, MD, discusses results from a study evaluating the omission of adjuvant radioactive iodine for patients with pediatric papillary thyroid carcinoma.
Luz Castellanos, MD, discusses results from a study evaluating the omission of adjuvant radioactive iodine for patients with pediatric papillary thyroid carcinoma.
Luz Castellanos, MD, discusses...
02/27/2025
Radiopharmaceutical Education Institute

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use